Macrogen Inc. (CEO Hyun-yong Jeong, www.macrogen.com), which is a precision medicine biotechnology company, announced on March 30, 2017 that it has acquired accreditation as an international authorized test agency for its forensic genetic relationship test from the Korea Laboratory Accreditation Scheme (KOLAS), which is a Korean accreditation organization under the Korean Agency for Technology and Standards, on March 3, 2017.
Macrogen has already acquired accreditation as an international certified test agency for “Forensic Genetics in the field of Forensics” from the German accreditation organization Deutsche Akkreditierungsstelle (DakkS) in December of last year. The accreditation by KOLAS is the second international accreditation in the field and proves that Macrogen holds world-class technology and reliability in genetic relationship testing.
With the accreditations from DAkkS and KOLAS, Macrogen can provide international certified test reports in accordance with the ISO/IEC 17025 international standard. As a result, the test reports in the field issued by Macrogen will have the same effect as the test reports issued in other countries in accordance with the mutual certification procedure in 94 countries that have joined the International Laboratory Accreditation Cooperation (ILAC). This means that Macrogen’s genetic relationship test reports can be used internationally.
Macrogen launched iD4UTM (www.id4u.com), which is a gene analysis service for general consumers, in April of last year. iD4UTM is a service that provides various genetic analysis results such as blood relationship tests and individual identification tests based on individual gene information. With this recognition, the reliability of the iD4UTM service has also increased to the highest level in the world. In addition, Macrogen will further strengthen the iD4UTM service for general consumers in the future and will actively expand the gene identification business together with government agencies, nonprofit organizations, international relief organizations, and the like.
Macrogen CEO Hyun-yong Jeong said, “Based on this accreditation as an international certified test agency, Macrogen is able to carry out various human ID service tasks in many countries in the future. We will give strength to the gene analysis project for 6.25 warriors and the DNA data building project for separated families in Korea, and will be able to participate in business such as the identification of the remains of people in war or disaster areas overseas.”
In addition, Macrogen also plans to actively participate in social contribution activities which can utilize its technology in this field in the future. Currently, the company is in the process of reviewing the business of finding the parents of adopted children overseas and is discussing this in close collaboration with adoption organizations in the United States. <The End>
Mikyung Kim, Senior Manager
Macrogen Inc., Management Innovation Dept.